• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在体药效学和动物的 PK/PD 研究。

In vitro Pharmacodynamics and PK/PD in Animals.

机构信息

Singapore General Hospital, Singapore, Singapore.

Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore, Singapore.

出版信息

Adv Exp Med Biol. 2019;1145:105-116. doi: 10.1007/978-3-030-16373-0_8.

DOI:10.1007/978-3-030-16373-0_8
PMID:31364074
Abstract

In the last decade, considerable advancements have been made to identify the pharmacokinetic/pharmacodynamic (PK/PD) index that defines the antimicrobial activity of polymyxins. Dose-fractionation studies performed in hollow-fiber models found that altering the dosing schedule had little impact on the killing or suppression of resistance emergence, alluding to AUC/MIC as the pharmacodynamic index that best describes polymyxin's activity. For in vivo efficacy, the PK/PD index that was the most predictive of the antibacterial effect of colistin against P. aeruginosa and A. baumannii was ƒAUC/MIC.

摘要

在过去的十年中,人们在确定能够定义多黏菌素类药物抗菌活性的药代动力学/药效学(PK/PD)指标方面取得了相当大的进展。在中空纤维模型中进行的剂量分割研究发现,改变给药方案对杀菌或抑制耐药性产生的影响很小,这表明 AUC/MIC 是最能描述多黏菌素类药物活性的药效学指标。对于体内疗效,预测多黏菌素对铜绿假单胞菌和鲍曼不动杆菌的抗菌作用的 PK/PD 指标是 ƒAUC/MIC。

相似文献

1
In vitro Pharmacodynamics and PK/PD in Animals.在体药效学和动物的 PK/PD 研究。
Adv Exp Med Biol. 2019;1145:105-116. doi: 10.1007/978-3-030-16373-0_8.
2
Pharmacokinetics/Pharmacodynamics of Pulmonary Delivery of Colistin against Pseudomonas aeruginosa in a Mouse Lung Infection Model.多黏菌素肺部给药在小鼠肺部感染模型中对铜绿假单胞菌的药代动力学/药效学研究
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02025-16. Print 2017 Mar.
3
Performances of the Rapid Polymyxin and Tests for Colistin Susceptibility Testing.快速检测多黏菌素和多黏菌素药敏试验的性能。
Microb Drug Resist. 2019 May;25(4):520-523. doi: 10.1089/mdr.2018.0153. Epub 2018 Dec 1.
4
fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models.FAUC/MIC 是预测黏菌素对鲍曼不动杆菌在小鼠大腿和肺部感染模型中疗效的最有预测价值的药代动力学/药效学指标。
J Antimicrob Chemother. 2010 Sep;65(9):1984-90. doi: 10.1093/jac/dkq226. Epub 2010 Jun 23.
5
New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection.在小鼠大腿和肺部感染模型中,对全身性给予多粘菌素治疗铜绿假单胞菌和鲍曼不动杆菌的新的药代动力学/药效学研究:肺部感染中的反应较小。
J Antimicrob Chemother. 2015 Dec;70(12):3291-7. doi: 10.1093/jac/dkv267. Epub 2015 Aug 27.
6
Elucidating the Pharmacokinetics/Pharmacodynamics of Aerosolized Colistin against Multidrug-Resistant Acinetobacter baumannii and Klebsiella pneumoniae in a Mouse Lung Infection Model.阐明雾化黏菌素治疗多重耐药鲍曼不动杆菌和肺炎克雷伯菌肺部感染的药代动力学/药效学。
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.01790-17. Print 2018 Feb.
7
A pharmacokinetic-pharmacodynamic (PKPD) model based on in vitro time-kill data predicts the in vivo PK/PD index of colistin.基于体外杀菌时间数据的药代动力学-药效学(PKPD)模型可预测黏菌素的体内PK/PD指标。
J Antimicrob Chemother. 2016 Jul;71(7):1881-4. doi: 10.1093/jac/dkw057. Epub 2016 Mar 16.
8
Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?“老”多黏菌素的药代动力学和药效学:有何新进展?
Diagn Microbiol Infect Dis. 2012 Nov;74(3):213-23. doi: 10.1016/j.diagmicrobio.2012.07.010. Epub 2012 Sep 6.
9
A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing.建立了一个药代动力学/药效学模型,用于评估多黏菌素对铜绿假单胞菌的体外作用,并对模拟细菌杀灭中的群体药代动力学变异性进行评估。
J Antimicrob Chemother. 2014 May;69(5):1350-61. doi: 10.1093/jac/dkt520. Epub 2014 Jan 27.
10
Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii.三种不同黏菌素甲磺酸钠(CMS)剂量方案在治疗多重耐药鲍曼不动杆菌感染危重症患者中的药代动力学和药效学差异。
Int J Antimicrob Agents. 2013 Aug;42(2):178-81. doi: 10.1016/j.ijantimicag.2013.04.018. Epub 2013 Jun 14.

引用本文的文献

1
Establishing Rationale for the Clinical Development of Cell Therapy Products: Consensus between Risk and Benefit.确立细胞治疗产品临床开发的基本原理:风险与获益之间的共识。
Int J Stem Cells. 2023 Feb 28;16(1):16-26. doi: 10.15283/ijsc21189. Epub 2022 Dec 31.
2
Pharmacokinetic/Pharmacodynamic Based Breakpoints of Polymyxin B for Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Pathogens.基于药代动力学/药效学的多粘菌素B对多重耐药革兰氏阴性病原体引起的血流感染的折点
Front Pharmacol. 2022 Jan 4;12:785893. doi: 10.3389/fphar.2021.785893. eCollection 2021.
3
Clinically Relevant Concentrations of Polymyxin B and Meropenem Synergistically Kill Multidrug-Resistant and Minimize Biofilm Formation.
多黏菌素B和美罗培南的临床相关浓度协同杀灭多重耐药菌并使生物膜形成最小化。
Antibiotics (Basel). 2021 Apr 8;10(4):405. doi: 10.3390/antibiotics10040405.